Daclatasvir recipients achieving protocol-defined response ( PDR ; HCV-RNA < lower limit of quantitation at Week @ and undetectable at Week @ ) were rerandomised at Week @ to continue daclatasvir/peginterferon-alfa -@ a/ribavirin for @weeks total duration or to placebo/peginterferon-alfa -@ a/ribavirin for another @weeks .